Interaction analysis between genetic polymorphisms and the efficacy/toxicity of chemotherapy in esophageal cancer

Interaction analysis between genetic polymorphisms and the efficacy/toxicity of chemotherapy in esophageal cancer - Interaction analysis between genetic polymorphisms and the efficacy/toxicity of chemotherapy in esophageal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008462

Enrollment

Registered

2012-07-18

Start date

2012-07-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

Combination chemotherapy with docetaxel/cisplatin/5-fluorouracil (docetaxel 60mg/sm day1, cisplatin 70mg/sm day1, 5-fluorouracil 600mg/sm day 1 to 5) given every 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients who will receive docetaxel/cisplatin/5-fluorouracil chemotherapy for advanced esophageal cancer (2) Pathologically proven squamous cell carcinoma of the esophagus (clinical stage II to IV) (3) Written informed consent is provided

Exclusion criteria

Exclusion criteria: Patients who are judged inappropriate for the entry into this study by the investigator

Design outcomes

Primary

Measure	Time frame
association between XPD, ERCC1, GSTP1,TS genetic polymorphisms and objective response with docetaxel/cisplatin/5-fluorouracil chemotherapy in esophageal cancer	—

Countries

Japan

Contacts

Public ContactYasuhiro Arakawa

Jikei university school of medicine Department of oncology and hematology

esophagus@jikei.ac.jp03-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026